±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 216  |  »Ø¸´: 5
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

lyh447lyh447

ÎÞ³æ (³õÈëÎÄ̳)

[½»Á÷] DGKzeta»ùÒò·½Ã漸¶Î+2009Äê12ÔÂ28ÈÕ

Plasmids and DNA Constructs¡ªRat DGK-IV cDNA was a generous
gift of K. Goto (Yamagata University School of Medicine, Sendai, Japan).
pSREflagDGKIV was excised with EcoRI, and the 3.4-kb fragment
encoding the DGK-IV cDNA was subcloned in the pcDNA3Myc
vector (pCDNAMycDGK-IV). For expression experiments, all constructs
were subcloned in the pEGFPBos vector in the GFP C terminus.
For the MCA construct, pCDNA3MycDGKIV was digested with BstXI/BglII, and the 2.2-kb fragment was subcloned in pEGFPBos. To generate
the ankyrin domains deletion (ANK), pCMV3MycDGKIV was
SacI-digested, blunted, KpnI-digested, and subcloned in pEGFPBos
digested with KpnI/SmaI. Site-directed mutagenesis was performed
using the QuikChange site-directed mutagenesis kit (Stratagene). To
generate the kinase-dead version of the enzyme, Gly-354 was replaced
with Asp as described (25). We designed two mutations in the MARCKS
homology domain; in the first we replaced Ser-259, Ser-266, Ser-271,
and Ser-272 with Ala (mutant Ser 3 Ala), and in the second the same
residues were replaced with Asp (mutant Ser 3 Asp). To mutate the
CRDs, the first conserved His in each of the two CRDs of the protein,
His-98 or His-173, were replaced with Gly either in the wild type
protein or in the Ser 3 Asp mutant. The C-terminal domain (CT)
construct, including the four ankyrin repeats and the PDZ-binding
motif, was generated by PCR with appropriate primers, which included
two restriction sites, SalI and XbaI. The PCR product was subcloned in
the pGEM-T easy vector (Promega) and then excised with SalI/XbaI to
be subcloned in the expression vector pEFBosCX-HA, which was previously
digested with SalI/XbaI.
Cell Lines and Transient Transfections¡ªCOS-7 cells were maintained
in Dulbecco¡¯s modified Eagle¡¯s medium supplemented with 10%
fetal bovine serum and 2 mM glutamine. For transfection, 60¨C80%
confluent cells were transfected with LipofectAMINE (Invitrogen) according to the manufacturer¡¯s instructions. After 24 h cells were harvested,
and each sample was divided into two pellets for immunoblot
and a DAG activity assay. The J-HM1-2.2 cell line was generated by
stable transfection of the human muscarinic subtype 1 receptor in the
Jurkat cell line (29). Cells were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 2 mM glutamine. Cells
(1.2  107) were transfected by electroporation with 20 g of DNA using
a Gene Pulser (Bio-Rad) at 270 V and a capacitance of 975 microfarads.
Cells were immediately transferred to 30 ml of growth medium and
assayed 24 h later.

Ï£Íû´ó¼ÒÖ§³Ö£¬ÎÒ²»Ì«¶®»ùÒò·½Ã棬ÎÒÏë×ödgk»ùÒòתȾ£¬µ«Õâ·½ÃæÎÒ²»»á£¡£¡£¡Ð»Ð»´ó¼ÒÎÒ£¬ÎÒ°ÉÈ«²¿Äóö£¬Ï£Íû´ó¼Ò°ï°ï棡£¡£¡Íò·Ö¸Ðл£¡£¡£¡

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sophia622

ľ³æ (СÓÐÃûÆø)

µÚÒ»¶Î

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+16,VIP+0):ÌØ±ð¸Ðл£¡£¡£¡ 12-27 00:08
ÖÊÁ£DNA¹¹½¨¡ª¡ªÊóDGK-IVµÄcDNAÓÉK.GotoÓÑÇéÌṩ£¨Yamagata University School of Medicine, Sendai, Japan£©pSREflagDgkIVÓÃEcoRIÇи±àÂëDGK-IV cDNAµÄ3.4kbµÄƬ¶ÎÑǿˡµ½pcDNA3MycÔØÌå(pCDNAMycDGK-IV£©¡£ÎªÁ˱í´ïʵÑ飬ËùÓй¹Ôì±»Ñǿˡµ½pEGFPBosÔØÌåGFPµ°°×µÄCÄ©¶ËÉÏ£»ÎªÁËMCAµÄ¹¹½¨£¬ÓÃBstXI/BglIIÏû»¯pCDNA3MycDGKIV£¬Ïû»¯²úÉúµÄ2.2kbµÄƬ¶ÎÑǿˡµ½pEGFPBosÉÏ¡£ÎªÁ˲úÉú궨µ°°×½á¹¹Óòɾ³ý£¨( ANK£©pCMV3MycDGKIVÓÃSacI¡¢KpnI½øÐÐ˫øÇУ¬²¢ÇÒÑǿˡµ½ÓÃKpnI/SmaIÏû»¯µÄpEGFPBosÔØÌåÉÏ¡£ÓÃQuikChange site-directed mutagenesisÊÔ¼ÁºÐ(Stratagene)¼ì²âλµãÖ±½ÓµÄÍ»±ä¡£ÎªÁ˲úÉúøµÄ¼¤Ã¸Ê§»î£¬Gly-354±»AspÌæ´ú£¨25£©¡£ÎÒÃÇÉè¼ÆÁË2¸öÍ»±äÔÚMARCKSͬԴ½á¹¹Óò£¬µÚÒ»¸öλµãÊÇSer-259, Ser-266, Ser-271ºÍSer-272Í»±ä³ÉAla£¨Í»±äSer 3 Asp)£¬µÚ¶þ¸öÏàͬµÄ²Ð»ù±»AspÈ¡´ú£¨Í»±äSer 3 Asp£©¡£ÎªÁËÍ»±äCRDsµ°°×Á½¸öCRDsµÄµÚÒ»¸ö±£ÊصÄHis£ºHis-98 »òHis-173ÔÚÒ°ÉúÐÍÖб»GlyÌæ´ú£¬ÔÚÍ»±äÐÍÖб»Ser 3 Asp¡£CÄ©¶Ë½á¹¹Óò¹¹½¨°üÀ¨Ãª¶¨µ°°×ÖØ¸´ÐòÁкÍPDZ½áºÏ»ùÐò£¬ÓúÏÊʵÄÓÐSalI ºÍXbaIøÇÐλµãµÄÒýÎï½øÐÐPCRÀ©ÔöµÄ·½·¨²úÉú¡£PCRµÄ²úÎïÑǿˡµ½pGEM-T easy£¨Promega£©ÔØÌåÖÐÈ»ºóÓÃSalI/XbaIøÇУ¬È»ºóÑǿˡµ½ÓÃSalI/XbaIøÇеıí´ïÔØÌåpEFBosCX-HAÉÏ¡£
2Â¥2009-12-26 21:08:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sophia622

ľ³æ (СÓÐÃûÆø)

µÚ¶þ¶Î

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
lyh447lyh447(½ð±Ò+10,VIP+0):·Ç³£¸Ðл£¡£¡£¡ 12-27 00:08
zap65535(½ð±Ò+3,VIP+0):ÖúÈËΪÀÖ 12-27 01:58
ϸ°ûϵºÍ˲ʱתȾ¡ª¡ªCOS-7ϸ°ûϵά³ÖÔÚ¼ÓÈë̥ţѪÇåºÍ2mM¹È°±õ£°·µÄDulbecco ¸ÄÁ¼ EagleµÄÅàÑø»ùÖУ¬ÎªÁËתȾ£¬60%-80%µÄÈÚºÏϸ°û°´ÕÕ˵Ã÷ÊéÓÃLipofectAMINE (Invitrogen)תȾ£¬24СʱºóÊÕ»ñϸ°û£¬Ã¿ÖÖÑùÆ··Ö×°³É2¸öС¹Ü£¬·Ö±ð×öÃâÒß³ÁµíʵÑéºÍDAG»îÐԲⶨ¡£J-HM1-2.2ϸ°ûϵÊÇÓÉJurkatϸ°ûϵÖÐÈËÀàÑÇÐÍ1¶¾Þ¦¼îÊÜÌåÎȶ¨×ªÈ¾²úÉú£¨29£©¡£²úÉúµÄϸ°û±£³ÖÔÚ¼ÓÓÐ10%µḀ̈ţѪÇåºÍ2mM¹È°±õ£°·µÄRPMI 1640ÅàÑø»ùÖС£
20  g µÄ DNAÓÃ270VºÍ975µçÈݵÄÂö³åÆ÷µçת»¯¾¢(1.2   107)ϸ°ûÖУ¬Ï¸°ûѸËÙ×ªÒÆµ½30mlÉú³¤ÅàÑø»ùÖÐÅàÑø24hºó²â¶¨
3Â¥2009-12-26 21:23:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lyh447lyh447

ÎÞ³æ (³õÈëÎÄ̳)

zap65535(½ð±Ò+0,VIP+0):¿ÉÒÔȥרҵ°æ¿éÌáÎÊ 12-27 01:57
·Ç³£¸Ðл£¡£¡£¡ÎÒÏëÓÃDGK-IV»ùÒòתȾÐļ¡Ï¸°û£¬²»ÖªµÀÕâλÅóÓÑÄܲ»ÄÜÔÚÕâ·½ÃæÖ¸µãһϣ¡£¡£¡±¾È˷dz£¸Ðл£¡£¡£¡ÄãÄܸøÎÒ»ØÌû£¬ÎÒÏàÐÅÎÒÃÇÊÇÓÐÔµµÄ£¡£¡£¡
4Â¥2009-12-27 00:12:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

sophia622

ľ³æ (СÓÐÃûÆø)

²»ºÃÒâ˼  ÎÒ²»ÊÇѧÕâ·½ÃæµÄ
5Â¥2009-12-27 11:56:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lyh447lyh447

ÎÞ³æ (³õÈëÎÄ̳)

ÄÇ»¹ÊǷdz£¸Ðл
6Â¥2009-12-27 12:04:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ lyh447lyh447 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¿É¿çרҵµ÷¼Á +3 ÖÜµÄµÃµØ 2026-04-04 6/300 2026-04-04 22:21 by barlinike
[¿¼ÑÐ] Çóµ÷¼Á +4 êɹ¦? 2026-04-03 4/200 2026-04-04 21:58 by hemengdong
[¿¼ÑÐ] 368Çóµ÷¼Á +5 ½ñ»ªÏ° 2026-04-03 7/350 2026-04-04 18:47 by imissbao
[¿¼ÑÐ] 333Çóµ÷¼Á +9 °¢¿ÆÒÝ 2026-03-31 9/450 2026-04-04 18:25 by macy2011
[¿¼ÑÐ] ÔõôɾÌû×Ó°¡ +3 ·ìêØ1000 2026-04-04 3/150 2026-04-04 14:20 by ÍÁľ˶ʿÕÐÉú
[¿¼ÑÐ] Çóµ÷¼Á +3 ũҵ¹¤³ÌÓëÐÅÏ¢¼ 2026-04-04 3/150 2026-04-04 12:19 by Éá¶øºóµÃ
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ²ÄÁϹ¤³Ì085601£¬Çóµ÷¼Á +17 cdyw 2026-04-02 18/900 2026-04-04 11:14 by w_xuqing
[¿¼ÑÐ] »¯¹¤µ÷¼Á303·Ö£¬¹ýËļ¶ +28 ÆÜÎà´ý·ç 2026-04-02 28/1400 2026-04-03 21:40 by qlm5820
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á +5 ´ºÈÕÀ´ÐÅ- 2026-04-03 5/250 2026-04-03 15:01 by buqi613
[¿¼²©] É격ÇóÖú +3 Reee1Llll 2026-04-01 3/150 2026-04-02 22:29 by ÕâÊÇÒ»¸öÎÞÁĵÄê
[¿¼ÑÐ] 366Çóµ÷¼ÁÒ»Ö¾Ô¸¶«±±´óѧ +8 ÔËÆøÀ´µÃÈôÓÐËÆÎ 2026-04-02 8/400 2026-04-02 21:39 by dongzh2009
[¿¼ÑÐ] 372·Ö²ÄÁÏÓ뻯¹¤£¨085600£©Ò»Ö¾Ô¸ºþÄÏ´óѧÇóµ÷¼Á +5 À¶¼ãƬ 2026-04-02 6/300 2026-04-02 21:37 by dongzh2009
[¿¼ÑÐ] 26¿¼Ñе÷¼Á +4 Wnz.20030617 2026-04-01 5/250 2026-04-02 16:11 by 1939136013¹·×³
[¿¼ÑÐ] 318Çóµ÷¼Á +3 óÆÐÐÖÂÔ¶. 2026-03-31 4/200 2026-04-02 15:56 by Jaylen.
[¿¼²©] ²ÄÁϹ¤³Ìרҵ˶ʿÉ격 +3 ÷ëÕýÓî 2026-03-30 3/150 2026-04-02 15:04 by greychen00
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£´ó²ÄÁϹ¤³Ì290Çóµ÷¼Á +20 Youth_ 2026-03-30 20/1000 2026-04-02 14:48 by 5896
[¿¼ÑÐ] ²ÄÁϹ¤³Ì322·Ö +8 ¹þ¹þ¹þºðºðºð¹þ 2026-04-01 8/400 2026-04-02 11:53 by 3041
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏÃÃÅ´óѧ»¯Ñ§¹¤³Ì£¨×¨Ë¶£©-Êý¶þÓ¢¶þ406·Ö-Çóµ÷¼Á +5 Ïô󻯹¤ 2026-04-01 5/250 2026-04-02 10:03 by jp9609
[¿¼ÑÐ] ÍÁľ304Çóµ÷¼Á +6 ÍÃͻͻͻ£¬ 2026-03-31 7/350 2026-04-02 09:06 by coolminer
[¿¼ÑÐ] 288×ÊÔ´Óë»·¾³×¨Ë¶Çóµ÷¼Á£¬²»ÏÞרҵ£¬ÓÐѧÉϾÍÐÐ +25 lllllos 2026-03-30 26/1300 2026-04-01 09:52 by Ò»Ö»ºÃ¹û×Ó?
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û